Matthew Boss, Head of Consumer Banking at Citizens Financial Group, filed a Form 4 on September 3, 2026, disclosing a disposition of common stock that occurred on September 1, 2026.
Stacie Schulz, Chief Accounting Officer of Methode Electronics Inc, filed a Form 4 on September 3, 2026, reporting the disposition of 1,649 shares of common stock on September 2, 2026, to satisfy tax obligations tied to the vesting of restricted stock units.
ZoomInfo Technologies Inc. CFO Michael Graham O'Brien filed a Form 4 on September 3, 2026, disclosing restricted stock unit vesting transactions and a tax-related share withholding that occurred on September 1, 2026.
Beta Bionics, Inc. (NASDAQ:BBNX) Chief Product Officer Mike Mensinger filed a Form 4 on September 3, 2026, reporting the sale of 4,375 shares of common stock on September 2, 2026, to cover tax withholding obligations tied to vesting restricted stock units.
Virginia Ruth Sanzone, VP and General Counsel of ICU Medical Inc/DE (NASDAQ:ICUI), filed a Form 4 on September 3, 2026, disclosing the sale of 4,856 shares of common stock across four transactions executed that same day under a pre-established Rule 10b5-1 trading plan.
Beta Bionics, Inc. Chief Medical Officer Steven Jon Russell filed a Form 4 on September 3, 2026, reporting the sale of common stock on September 2, 2026, to cover tax withholding obligations tied to the vesting of restricted stock units.
Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc. (NASDAQ:BBNX), filed a Form 4 on September 3, 2026, disclosing the sale of 5,327 shares of common stock on September 2, 2026, to cover tax withholding obligations associated with the vesting of restricted stock units.
Norman D. Schwartz, Chairman and CEO of Bio-Rad Laboratories, Inc., filed a Form 4 on September 3, 2026, disclosing transactions in Bio-Rad Class A common stock on September 1, 2026, stemming from the vesting of restricted stock units.
Allison Schwartz, a director of Bio-Rad Laboratories, Inc., filed a Form 4 on September 3, 2026, disclosing transactions in Bio-Rad Class A common stock on September 1, 2026, stemming from the vesting of restricted stock units.
James Barry, Executive Vice President and President of the Life Science Group at Bio-Rad Laboratories, Inc., filed a Form 4 on September 3, 2026, reporting restricted stock unit vestings and a related share withholding transaction dated September 1, 2026.